Pacer Advisors Inc. bought a new position in shares of Avanos Medical, Inc. (NYSE:AVNS - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 422,612 shares of the company's stock, valued at approximately $6,056,000. Pacer Advisors Inc. owned 0.92% of Avanos Medical as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of AVNS. Vanguard Group Inc. lifted its stake in shares of Avanos Medical by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 5,339,778 shares of the company's stock valued at $85,009,000 after purchasing an additional 19,476 shares during the period. T. Rowe Price Investment Management Inc. raised its position in shares of Avanos Medical by 27.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company's stock worth $47,941,000 after purchasing an additional 644,267 shares during the last quarter. Brown Advisory Inc. lifted its position in shares of Avanos Medical by 1.4% in the first quarter. Brown Advisory Inc. now owns 1,931,163 shares of the company's stock valued at $27,674,000 after acquiring an additional 26,069 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Avanos Medical by 4.9% in the fourth quarter. Northern Trust Corp now owns 526,763 shares of the company's stock worth $8,386,000 after acquiring an additional 24,720 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. increased its position in shares of Avanos Medical by 43.1% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company's stock worth $7,874,000 after purchasing an additional 148,902 shares in the last quarter. Hedge funds and other institutional investors own 95.17% of the company's stock.
Avanos Medical Price Performance
Shares of Avanos Medical stock traded down $0.31 during trading hours on Thursday, reaching $11.36. 114,986 shares of the company's stock were exchanged, compared to its average volume of 498,279. The business has a fifty day moving average of $12.16 and a two-hundred day moving average of $13.66. The company has a quick ratio of 1.56, a current ratio of 2.57 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $525.47 million, a P/E ratio of -1.36 and a beta of 1.12. Avanos Medical, Inc. has a 1 year low of $11.14 and a 1 year high of $25.36.
Avanos Medical (NYSE:AVNS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.07. The company had revenue of $167.50 million during the quarter, compared to analysts' expectations of $161.75 million. Avanos Medical had a positive return on equity of 6.26% and a negative net margin of 55.80%. The firm's quarterly revenue was up .8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.22 earnings per share. As a group, research analysts predict that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.
About Avanos Medical
(
Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Further Reading
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
